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Background:  Many patients on lipid-lowering therapies (LLT) are unable to achieve target LDL cholesterol (LDL-C) levels. This double-blind phase 
3 study examined the safety and efficacy of mipomersen (Mipo), an apolipoprotein (apo) B synthesis inhibitor, in hypercholesterolemic patients at 
high CHD risk (NCEP-ATP III).
Methods:  Adults (≥ 18 years) on maximally tolerated statin ± ezetimibe, bile-acid sequestrants, and/or niacin with LDL-C ≥ 100 mg/dL and TG 
< 200 mg/dL were randomized (2:1) to Mipo 200 mg or placebo (Pbo) sc weekly for 26 weeks. The primary endpoint was % LDL-C change from 
baseline (BL) at Week 28 or 2 weeks after last dose if treatment was not completed. Additional endpoints included apo B, total-C, non-HDL-C and 
lipoprotein (Lp)(a).
Results:  One hundred fifty-eight patients were randomized (105 Mipo; 53Pbo), including 88 (56%) patients with type 2 diabetes (55% Mipo, 
58% Pbo). At BL all patients were taking a statin (63 on maximal approved dose [41% Mipo; 38% Pbo)]) with 25 patients (18% Mipo, 12% Pbo) on 
ezetimibe. Mean (95%CI) % change in LDL-C from BL was -37% (-42, -32) with Mipo vs -5% (-11, 2) with Pbo ( p<0.001). Significant reductions also 
occurred for apo B (38%), total-C (26%), non-HDL-C (36%), and Lp(a) (24% ), all p<0.001 vs Pbo], with no change in HDL-C. LDL-C <70 mg/dL was 
attained in 50% Mipo patients vs 4% in Pbo. Forty-five (43%) Mipo and 9 (17%) Pbo patients withdrew from the trial (26 Mipo, 2 Pbo for adverse 
events [AE]). Common on-treatment AEs included injection site reactions (78% Mipo, 31% Pbo) and flu-like symptoms (34% Mipo, 21% Pbo). No Pbo 
patients had ALT elevations ≥3 × ULN; 15 (14%) Mipo patients had ALT elevations ≥3 × ULN, without concomitant significant bilirubin elevations; 
10 patients (10%) occurring on consecutive measurements at least 7 days apart. 1 patient had ALT ≥10 × ULN. There were 13 on-treatment SAEs [7 
Mipo (1 possibly related), 6 Pbo (1 death)]. Results were similar in patients with and without diabetes.
Conclusions:  Mipo 200 mg s.c. weekly significantly reduced LDL-C and other atherogenic lipids and lipoproteins in patients at high CHD risk with 
LDL-C > 100 mg/dL despite maximally tolerated statin therapy. Safety findings were consistent with prior studies.
